All Oncology News

The FDA has approved cilta-cel for select patients with relapsed/refractory multiple myeloma who have received at least 1 line of therapy, and who are lenalidomide refractory.

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

The FDA granted accelerated approval to trastuzumab deruxtecan for pretreated, unresectable or metastatic HER2-positive solid tumors.

Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.

Gita Suneja, MD, MS, has been named the senior director of Programs to Enhance Diversity at Huntsman Cancer Institute.

RNX-051 displays impact on bacterial biomass in patients with right-sided colorectal cancer and right-sided colon polyps/adenomas.

Durvalumab monotherapy showed clinical benefit in limited-stage small cell lung cancer, according to data from the phase 3 ADRIATIC trial.

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Afami-cel displayed activity in a heavily pretreated population of patients with advanced synovial sarcoma or myxoid round cell liposarcoma.

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Eduardo M. Sotomayor, MD, expands on the evolving treatment paradigm for hematologic malignancies, highlighting treatment with CAR T-cell therapy.

Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.

Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.

Positive phase 2 findings for CAN-2409 plus valacyclovir in pancreatic ductal adenocarcinoma have been reported.

Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.

Debra L. Richardson, MD, FACS, FACOG, expands on results with upifitamab rilsodotin in platinum-resistant high-grade serous ovarian cancer.

Phillip J. Koo, MD, highlights future directions regarding PSMA PET imaging and key takeaways from a presentation he gave on the precision imaging tool.

Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.

Phillip J. Koo, MD, discusses how PSMA PET will be used in clinical trials, the RADAR VI guidelines for using the precision imaging tool, and more.

Stereotactic ablative body radiotherapy elicited high local control rates in patients with renal cell carcinoma who did not undergo surgical resection.

Carlos L. Arteaga, MD, discusses the utility of vepdegestrant alone or in combination in patients with ER-positive, HER2-negative advanced breast cancer.

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

Anthony Villano, MD, and Joceline Vu, MD, were recently elected members of the Education Committee of the Association for Academic Surgery.

The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.

The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.

Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.